search
Company Information
USD
0.71
- (-2.7%)
NASDAQ:CTXR, CITIUS PHARMACEUTICALS, INC.
Industry: Biotechnology
End of Day: 2 May 2024 GMT-4
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates:  LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Address

11 Commerce Drive
First Floor

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Mr. Dennis M. McGrath, C.P.A.
Director
Mr. Myron Z. Holubiak
Director/Vice Chairman of the Board
Mr. Leonard L. Mazur
CEO/CEO, Subsidiary/Chairman of the Board/Director/President, Subsidiary/Secretary/Secretary, Subsidiary
Mr. Suren G. Dutia
Director
Ms. Carol Webb
Director
Dr. Eugene Holuka
Director
Mr. Jaime Bartushak
CFO/Chief Accounting Officer/Other Executive Officer
Dr. Myron Czuczman
Chief Medical Officer/Executive VP
Mr. Robert J. Smith
Director

Ownership

Institution Holdings

BlackRock Inc
8,457,814 (5.316%)
Vanguard Group Inc
6,900,230 (4.337%)
BlackRock Fund Advisors
4,343,818 (2.730%)
Vanguard Investments Australia Ltd
4,132,683 (2.598%)
Geode Capital Management, LLC
2,779,908 (1.747%)
Fidelity Management & Research Company LLC
2,605,784 (1.638%)
State Street Corporation
2,207,361 (1.387%)
Northern Trust Investments Inc
1,756,732 (1.104%)
State Street Global Advisors
1,529,047 (0.961%)
Northern Trust Corp
1,045,135 (0.657%)

Funds Holdings

iShares Russell 2000 ETF
2,969,586 (1.867%)
iShares Russell 2000 Value ETF
972,053 (0.611%)
Fidelity Extended Market Index Fund
821,739 (0.517%)
Vanguard Russell 2000 Index Fund
406,455 (0.255%)
BlackRock - Extended Mkt Fund CF
268,415 (0.169%)
BlackRock Extended Equity Market
231,004 (0.145%)
Russell 2000 Index Non-Lendable Fund E
194,884 (0.123%)
NT Extended Equity Market Idx Fd - NL
181,436 (0.114%)
BlackRock Russell 2500™ Index
180,916 (0.114%)
NT Ext Equity Mkt Idx Fd - DC - NL
145,719 (0.092%)

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow
Make Smart Investment Choices